Note: Descriptions are shown in the official language in which they were submitted.
WO 94/13254 PCT/US93/11989
ANTIPLAQUE, ANTIGINGIVITIS, ANTICARIES ORAL COMPOSITION
FIELD OF THE INVENTION
The present invention relates to an antiplaque, antigingivitis,
anticaries oral composition. More particularly, the present invention relates
to an
oral composition containing N-methylpyrrolidone alone or in combination with a
noncationic antibacterial compound.
1 0 BACKGROUND OF THE INVENTION
Oral compositions which inhibit calculus formation on dental
surfaces are highly desirable since calculus is one of the causative factors
in
periodontal conditions. The reduction of calculus, therefore, promotes oral
hygiene. Polyphosphates, such as tetraalkali metal pyrophosphates, are
1 5 examples of anticalculus agents.
Dental plaque is a precursor of calculus. Unlike calculus, however,
plaque may form on any part of the tooth surface, particularly at the gingival
margin. Hence, besides being unsightly, it is implicated in the occurrence of
2 0 gingivitis.
Accordingly, it is desirable to include effective antiplaque agents in
oral compositions, optionally in combination with an anticalculus agent.
Antiplaque agents found particularly effective are noncationic antibacterial
2 5 agents, such as halogenated diphenyl ethers, especially Triclosan
(2',4',4'-2-
trichloro-2-hydroxy-diphenyl ether), as disclosed in Gaffar et al., U.S.
Patent No.
5,037,637, incorporated herein by reference. However, since halogenated
WO 94/13254 PCT/US93/11989
diphenyl ethers and other noncationic antibacterial agents are not readily
soluble in water, alternate solvents are desirable to optimize their
effectiveness.
Pyrrolidone compounds, other than N-methylpyrrolidone, have
previously been employed for a variety of purposes in oral compositions. For
example, Roberts et al., U.S. Reissue Patent No. 29,634 discloses the use of
polyvinyl pyrrolidone (PVP) as a binder to form a polishing agent into
agglomerated particles. PVP is disclosed as a viscosity adjuster in Prussin,
U.S.
1 0 Patent No. 3,954,962, as a gelling agent in Norfleet, U.S. Patent No.
3,840,657, a
cooling agent in Humbert et al., U.S. Patent No. 3,917,613, and a synthetic
gum
in Aguilar U.S. Patent No. 4,344,931. PVP is further disclosed for uses in
other
oral compositions with hydrogen peroxide. Both Simon et al, U.S. Patent Nos.
4,521,403 and 4,567,036 teach to the use of PVP with hydrogen peroxide in
1 5 controlling disease of the teeth and periodontum. Merianos et al, U.S.
Patent No.
5,130,124 teaches to the use of PVP as a film forming antimicrobial
composition
when combined with hydrogen peroxide.
Pyrrolidone compounds have also been incorporated into dentifrice
2 0 compositions to kill bacteria and/or retard the formation of plaque and
tartar.
Ploger et al., U.S. Patent No. 3,960,888, disclose pyrrolidone-5,5-
diphosphonic
acids as antitartar and antiplaque agents. Murdrak, U.S. Patent No. 2,757,125,
discloses N-higher alkyl-4-carboxy-2-pyrrolidones as antibacterial agents for
oral
compositions. Login et al., U.S. Patent Nos. 4,732,990; 4,830,850; and
2 5 4,837,013 disclose quaternized nitrogen compounds including derivatives of
pyrrolidone as antibacterial agents for dentifrice compositions and/or
mouthwashes.
2
WO 94/13254 ' ~ 1 ~ ~ PCT/US93/11989
Substituted pyrrolidone compounds have been used to retard
plaque formation as disclosed in Blackburne et al, U.S. Patent No. 4,093,711;
Shapiro et al., U.S. Patent Nos. 4,117,107 and 4,117,108; and Hollister, U.S.
Patent No. 4,621,120.
Dunn et al, U.S. Patent No. 4,975,271, teaches to use N-
methylpyrrolidone as one of several skin penetration enhancer solvents for a
drug or bioactive agent which is applied directly to oral mucosa. Dental
surfaces
are not contacted. Mouthrinses and other topically applied oral medicinal
agents
1 0 which would contact dental surfaces as well as oral mucosa are
specifically
excluded.
It would be desirable to enhance the solubility of noncationic
antibacterial agents to improve their effectiveness. It would also be
desirable to
1 5 provide an oral composition containing an antiplaque agent with enhanced
antiplaque effectiveness.
SUMMARY OF THE INVENTION
2 0 In accordance with the present invention N-methylpyrrolidone [1-
methyl-2-pyrrolidone (1)J has been found to have a potent antiplaque effect
when
employed in an oral composition alone and to enhance the effect of noncationic
antibacterial agents such as halogenated diphenyl ethers, particularly
Triclosan
in the prevention of plaque, gingivitis and caries.
The present invention is directed to an oral composition comprising
an orally acceptable vehicle suitable for topically contacting dental surfaces
and
gums and up to about 20% by weight N-methylpyrrolidone as an antiplaque
3
WO 94/13254 PCT/US93/11989
2'.5193'
agent in the presence or absence of an antibacterial agent, preferably a
substantially water-insoluble noncationic antibacterial agent.
The amount of N-methylpyrrolidone in this invention is typically
about 0.5 to 20% by weight based on the total weight of the dental composition
and preferably about 1 to 15% and most preferably about 5 to 10%. Gum
irritation can be avoided when N-methylpyrrolidone is used in amounts of up to
about 20% by weight of the topically applied oral composition.
1 0 A further aspect of the invention is a method for reducing plaque
formation comprising topically contacting dental surfaces and gums with an
oral
composition comprising a liquid vehicle suitable for topically contacting
dental
surfaces and gums and as an antiplaque agent, up to about 20% N-
methylpyrrolidone based on the total weight of the composition. Preferably,
the
1 5 composition is contacted with dental surfaces and gums about 1 to 3 times
a day.
The composition and process may include one or more
antibacterial agents which are particularly desirable from consideration of
antiplaque effectiveness, safety and formulation.
DETAILED DESCRIPTION OF THE INVENTION
The following antibacterial agents may be incorporated into the oral
2 5 composition of the present invention:
HALOGENATED DIPHENYL ETHERS
2',4,4'-trichloro-2-hydroxy-diphenyl ether (Triclosan)
2,2'-dihydroxy-5,5'-dibromo-diphenyl ether
4
WO 94113254 21519 3 7 PCT/US93/11989
PHENOLIC COMPOUNDS
(including phenol and its homologs, mono- and poly-alkyl and aromatic
halophenols, resorcinol and its derivatives and bisphenolic compounds and
PHENOL AND ITS HOMOLOGS
PHENOL
2 Methyl - Phenol
3 Methyl - Phenol
4 Methyl - Phenol
4 Ethyl - Phenol
1 5 2,4-Dimethyl - Phenol
2,5-Dimethyl - Phenol
3,4-Dimethyl - Phenol
2,6-Dimethyl - Phenol
4-n-Propyl - Phenol
2 0 4-n-Butyl - Phenol
4-n-Amyl - Phenol
4-tert-Amyl - Phenol
4-n-Hexyl - Phenol
4-n-Heptyl - Phenol
25
MONO- AND POLY-ALKYL AND AROMATIC HALOPHENOLS
Methyl - p-Chlorophenol
Ethyl - p-Chlorophenol
3 0 n-Propyl - p-Chlorophenol
n-Butyl - p-Chlorophenol
n-Amyl - p-Chlorophenol
sec.-Amyl - p-Chlorophenol
n-Hexyl - p-Chlorophenol
3 5 Cyclohexyl - p-Chlorophenol
n-Heptyl - p-Chlorophenol
n-Octyl - p-Chlorophenol
4 0 O-CHLOROPHENOL
Methyl - o-Chlorophenol
Ethyl - o-Chlorophenol
n-Propyl - o-Chlorophenol
4 5 n-Butyl - o-Chlorophenol
n-Amyl - o-Chlorophenol
tert-Amyl - o-Chlorophenol
n-Hexyl - o-Chlorophenol
n-Heptyl - o-Chlorophenol
50
5
WO 94/13254 PCT/US93/11989
p-CHLOROPHENOL
o-Benzyl - p-Chlorophenol
o-Benzyl-m-methyl - p-Chlorophenol
o-Benzyl-m, m-dimethyl - p-Chlorophenol
o-Phenylethyl - p-Chlorophenol
o-Phenylethyl-m-methyl - p-Chlorophenol
3-Methyl - p-Chlorophenol
3,5-Dimethyl - p-Chlorophenol
1 0 6-Ethyl-3-methyl - p-Chlorophenol
6-n-Propyl-3-methyl - p-Chlorophenol
2-iso-Propyl-3-methyl - p-Chlorophenol
2-Ethyl-3,5-dimethyl - p-Chlorophenol
6-sec. Butyl-3-methyl - p-Chlorophenol
1 5 2-iso-Propyl-3,5-dimethyl - p-Chlorophenol
6-Diethylmethyl-3-methyl - p-Chlorophenol
6-iso-Propyl-2-ethyl-3-methyl - p-Chlorophenol
2-sec. Amyl-3,5-dimethyl - p-Chlorophenol
2-Diethylmethyl-3,5-dimethyl - p-Chlorophenol
2 0 6-sec. Octyl-3-methyl - p-Chlorophenol
p-BROMOPHENOL
Methyl - p-Bromophenol
Ethyl - p-Bromophenol
n-Propyl - p-Bromophenol
n-Butyl - p-Bromophenol
3 0 n-Amyl - p-Bromophenol
sec-Amyl - p-Bromophenol
n-Hexyl - p-Bromophenol
cyclohexyl - p-Bromophenol
3 5 o-BROMOPHENOL
tert.-Amyl - o-Bromophenol
n-Hexyl - o-Bromophenol
n-Propyl-m,m-Dimethyl - o-Bromophenol
2-Phenyl Phenol
4-chloro-2-methyl phenol
4-chloro-3-methyl phenol
4-chloro-3,5-dimethyl phenol
4 5 2,4-dichloro-3,5-dimethyl phenol
3,4,5,6-terabromo-2-methyl phenol
5-methyl-2-pentylphenol
4-isopropyl-3-methylphenol
5-chloro-2-hydroxydiphenylmethane
RESORCINOL AND ITS DERIVATIVES
6
2151937 ~~~'-''~ 9;~/~~
!P
.. ~l ~,j j ~ - F'8 l9
RESORCINOL
Methyl - Resorcinol
Ethyl - Resorcinol
5 n-propyl - Resorcinol
n-Butyl - Resorcinol
n-Amyl - Resorcinol
n-Hexyl - Resorcinol
n-Heptyl - Resorcinol
10 n-Octyl - Resorcinol
n-Nomyl - Resorcinol
Phenyl - Resorcinol
Benzyl - Resorcinol
Phenylethyl - Resorcinol
15 Phenylpropyl - Resorcinol
p-Chlorobenzyl - Resorcinol
5-Chloro 2,4-Dihydroxydiphenyl Methane
4'-Chloro 2,4-Dihydroxydiphenyl Methane
5-Bromo 2,4-Dihydroxydiphenyl Methane
20 4'-Bromo 2,4-Dihydroxydiphenyl Methane
BISPHENOLIC COMPOUNDS
2,2'-methylene bis (4-chlorophenol)
25 2,2'-methylene bis (3,4,6-trichlorophenol)
2,2'-methylene bis (4-chloro-6-bromophenol)
bis (2-hydroxy-3,5-dichlorophenyl) sulfide
bis (2-hydroxy-5-chlorobenzyl) sulfide
30 HALOGENATED CARBANILIDES
3,4,4'-trichlorcarbanilide
3-trifluoromethyl-4,4'-dichlorocarbanilide
3,3',4-trichlorocarbanilide
35 The preferred noncationic antibacterial agent, when employed, is
present in the oral composition in an effective antiplaque amount, typically
about
0.01 to 5% by weight, preferably about 0.03 to 1Q/° by weight. This
antibacterial
agent is substantially water-insoluble, meaning that its solubility is less
than about
1 % by weight in water at 25°C and may be even less than about 0.01 %
by weight.
40 The solubility of the antibacterial agent is increased by the addition of
an effective
7
A~tE~I?~D
WO 94/13254 21519 3 7
PCT/US93/11989
amount of n-methylpyrrolidone. As a consequence, a greater amount of the
antibacterial agent is delivered to the teeth where plaque is likely to
develop.
The preferred halogenated diphenyl ether is Triclosan. The
preferred phenolic compounds are n-hexyl resorcinol and 2,2'-methylene bis (4-
chloro-6-bromophenol). The most preferred antibacterial antiplaque compound
is Triclosan. Triclosan is described in more detail in Gaffar et al., U.S.
Patent No.
5,037,637, and references cited therein, each of which is incorporated herein
by
reference.
Cationic antibacterial agents may optionally be employed in the
1 0 compositions of the present invention. Such agents are disclosed in, for
example, Gaffar, U.S. Patent No. 4,339,430, incorporated herein by reference,
and include antibacterial quaternary ammonium compounds such as
benzethonium chloride and dissobutylphenoxyethoxyethyl dimethyl benzyl
ammonium chloride.
1 S Other antibacterial antiplaque quaternary ammonium compounds
include those in which one or two of the substituents on the quaternary
nitrogen
has a carbon chain length (typically an alkyl group) of some 8 to 20,
typically 10
to 18, carbon atoms while the remaining substituents have a lower number of
carbon atoms (typically alkyl or benzyl group), such as 1 to 7 carbon atoms,
2 0 typically methyl or ethyl groups. Dodecyl trimethyl ammonium bromide,
dodecyl
dimethyl (2-phenoxyethyl) ammonium bromide, benzyl dimethyl stearyl
ammonium chloride, cetylpyridinium chloride and quaternized 5-amino-1,3-bis
(2-ethyl-hexyl)-5-methyl hexa hydropyrimidine are exemplary of other typical
quaternary ammonium antibacterial agents.
2 5 Other types of cationic antibacterial agents which are desirably
incorporated in the present composition include the amidines such as
substituted
guanidines e.g. chlorhexidine and the corresponding compound, alexidine,
8
WO 94/13254 PCT/US93/11989
having 2-ethylhexyl groups instead of chlorophenyl groups, as well as other
known bis-biguanides.
Cationic tertiary amines may also be used and include those
having one fatty alkyl group (typically 12 to 18 carbon atoms) and 2
poly(oxyethylene) groups attached to the nitrogen (typically containing a
total of
from 2 to 50 ethenoxy groups per molecule) and salts thereof with acids and
compounds of the structure:
(CH 2 Q-I2 O)Z H
(CHZ ~-i2 O) X H
R N ~2 ~2 N
(CHZ Q~ 2 O) Y H
where R is a fatty alkyl group containing 12 to 18 carbon atoms and x, y, and
z
total 3 or higher, as well as salts thereof.
Cationic antibacterial agents which may be employed in the
practice of this invention are typically employed in amounts such that the
oral
product contains about 0.001 to 15% by weight of the agent, preferably about
0.01 to 5% by weight, and most preferably about 0.25 to 1.0% by weight
referring
to its free base form, based on the total weight of the oral composition.
2 0 Other cationic antibacterial agents for use in the present invention
are described in Gaffar, U.S. Patent No. 4,339,430, and references mentioned
therein.
The present oral composition preferably contains an anticalculus agent.
The preferred anticalculus agents are linear molecularly dehydrated
9
'' a'~ ~'. J ,
215 I 9 3 '7 , l PEA,
polyphosphate salts which are well known, being generally employed in the form
of their wholly or partially neutralized water-soluble alkali metal (e.g.
potassium
and preferably sodium) or ammonium salts, and any mixtures thereof.
Representative examples include sodium hexametaphosphate, sodium
S tripolyphosphate, disodium diacid, trisodium monoacid and tetrasodium
pyrophosphates and the like. The anticalculus agents are generally employed in
the instant oral compositions in approximate amounts of about 0.1 to 7% by
weight, more preferably about 2 to 7% by weight.
Particularly desirable anticalculus agents of the polyphosphate type
are tetraalkali metal pyrophosphates, including mixtures thereof, such as
tetrasodium pyrophosphate, tetrapotassium pyrophosphate and mixtures thereof.
An anticalculus agent comprising about 4.3% to 7% by weight of the oral
compositions wherein the weight ratio of tetrapotassium pyrophosphate to
tetrasodium pyrophosphate is from about 4.3:2.7 to about 6:1 is especially
preferred.
In order to optimize the effectiveness of the oral composition, if one
or more polyphosphate compounds are present, inhibitors against enzymatic
hydrolysis of the polyphosphate are desirably present. Such inhibitors include
a
fluoride ion source and/or synthetic anionic polymeric polycarboxylates.
The sources of fluoride ions, or fluorine-providing component, as the
acid phosphatase and pyrophosphatase enzyme inhibitor component, are well
known in the art as anti-caries agents. These compounds may be slightly
soluble
in water or may be fully water-soluble. They are characterized by their
ability to
release fluoride ions in water, by their freedom from undesired reaction with
other
compounds of the oral preparation and by their anticaries and enzyme
inhibitory
activity. Among these materials are inorganic fluoride salts, such as soluble
alkali
metal, alkaline earth metal salts, for example, sodium fluoride, potassium
fluoride,
ammonium fluoride, calcium
~ME~ID~D .
WO 94/13254 PCT/US93111989
21~193'~
fluoride, a copper fluoride such as cuprous fluoride, zinc fluoride, barium
fluoride,
sodium fluorosilicate, ammonium fluorosilicate, sodium fluorozirconate, sodium
monofluorophosphate, aluminum mono- and di-fluorophosphate, and fluorinated
sodium calcium pyrophosphate. Alkali metal and tin fluorides, such as sodium
and stannous fluorides, sodium monofluorophosphate (MFP) and mixtures
thereof, are preferred.
The amount of fluorine-providing compound is dependent to some
extent upon the type of compound, its solubility, and the type or oral
preparation,
but it must be a non-toxic amount, generally about 0.005 to about 3.0% in the
1 0 preparation. In a dentifrice preparation, e.g. dental gel, toothpaste
(including
cream), tooth powder, or dental tablet, an amount of such compound which
releases up to about 5,000 ppm of fluoride ion by weight of the preparation is
considered satisfactory. Any suitable minimum amount of such compound may
be used, but it is preferable to employ sufficient compound to release about
300
1 5 to 2,000 ppm, more preferably about 800 to about 1,500 ppm of fluoride
ion.
Typically, in the cases of alkali metal fluorides, this component is
present in an amount up to about 2% by weight, based on the weight of the
preparation, and preferably in the range of about 0.05% to 1 %. In the case of
sodium monofluorophosphate, the compound may be present in an amount of
2 0 about 0.1 to 3%, more typically about 0.76%.
In dentifrice preparations such as lozenges and chewing gum, the
fluorine-providing compound is typically present in an amount sufficient to
release up to about 500 ppm, preferably about 25 to 300 ppm by weight of
fluoride ion. Generally about 0.005 to 1.0% by weight of such compound is
2 5 present.
Synthetic anionic polymeric polycarboxylates useful as enzyme
inhibitors, particularly to inhibit alkaline phosphatase, may optionally
enhance
the antibacterial effect of the substantially water-insoluble noncationic
11
~~r 1 ~~,'~ 9 . ~ i I
~ 1519 3'~ 1~~~~, ~ -
antibacterial agents such as Triclosan. Examples of these polycarboxylates are
disclosed in Shedlovsky U.S. Patent No. 3,429,963, Dichter et al. U.S. Patent
No.
3,956,480, Gaffar U.S. Patent Nos. 4,138,477 and 4,152,420, and Gaffar et al.
U.S. Patent No. 4,183,914, each incorporated herein by reference.
The synthetic anionic polymeric polycarboxylates optionally but
preferably employed herein are, as indicated above, well known, being often
employed in the form of their free acids or preferably partially or more
preferably
fully neutralized water-soluble alkali metal (e.g, potassium and preferably
sodium)
or ammonium salts. Preferred are 1:4 to 4:1 copolymers of malefic anhydride or
acid with another polymerizable ethylenically unsaturated monomer, preferably
methyl vinyl ether (malefic anhydride) having a molecular weight (M.W.) of
about
30,000 to 1,000,000. These copolymers are available for example as Gantrez AN
139 (M.W. 500,000), AN 119 (M.W. 250,000); and preferably S-97 Pharmaceutical
Grade of GAF Corporation. The term "synthetic" is intended to exclude known
thickening or gelling agents comprising carboxymethylcellulose and other
derivatives of cellulose and natural gums.
Other operative polymeric polycarboxylates include those disclosed
in Dichter et al., U.S. Patent No. 3,956,480, referred to above, such as the
1:1
copolymers of malefic anhydride with ethyl acrylate, hydroxyethyl
methacrylate, N-
vinyl-2-pyrrolidone, or ethylene, the latter being available for example as
Monsanto EMA No. 1103, M.W. 10,000 and EMA Grade 61, and 1:1 copolymers
of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl
acrylate,
isobutyl vinyl ether or N-vinyl-2-pyrrolidone.
Additional operative polymer polycarboxylates disclosed in above
referred to Gaffar, U.S. Patent No. 4,138,477, and Gaffar et al., U.S. Patent
No.
4,183,914, include copolymers of malefic anhydride with styrene, isobutylene
or
ethyl vinyl ether, polyacrylic, polyitaconic and polymaleic acids, and
sulfoacrylic
oligomers of M.W. as low as 1,000, available as Uniroyal ND-2.
12
:,~nc,~;~ ;
WO 94/13254
PCT/US93/11989
Suitable generally are polymerized olefinically or ethylenically
unsaturated carboxylic acids containing an activated carbon-to-carbon olefinic
double bond and at least one carboxyl group, that is, an acid containing an
olefinic double bond which readily functions in polymerization because of its
presence in the monomer molecule either in the alpha-beta position with
respect
to a carboxyl group or as part of a terminal methylene grouping. Illustrative
of
such acids are acrylic, methacrylic, ethacrylic, alpha-chloroacrylic,
crotonic, beta-
acryloxy propionic, sorbic, alpha-chlorsorbic, cinnamic, beta-styrilacrylic,
muconic, itaconic, citraconic, mesaconic, glutaconic, aconitic, alpha-
1 0 phenylacrylic, 2-benzyl acrylic, 2-cyclohexylacrylic, angelic, umbellic,
fumaric,
malefic acids and anhydrides. Other different olefinic monomers
copolymerizable
with such carboxylic monomers include vinyl acetate, vinyl chloride, dimethyl
maleate and the like. Copolymers contain sufficient carboxylic salt groups for
water-solubility.
1 5 Also useful herein are so-called carboxyvinyl polymers disclosed
as toothpaste components in Chown et al. U.S. Patent No. 3,980,767; Roberts et
al. U.S. Patent No. 3,935,306; Perla et al. U.S. Patent No. 3,919,409;
Harrison
U.S. Patent No. 3,911,104, and Colodney et al. U.S. Patent No. 3,711,604. They
are commercially available for example under the trademarks Carbopol 934, 940
2 0 and 941 of B.F. Goodrich, these products consisting essentially of a
colloidally
water-soluble polymer of polyacrylic acid cross-linked with from about 0.75%
to
2.0% by weight of polyallyl sucrose or polyallyl pentaerythritol as cross-
linking
agent.
The synthetic anionic polymeric polycarboxylate component is
2 5 mainly a hydrocarbon with optional halogen and 0-containing substituents
and
linkages as present in for example ester, ether and OH groups, and when
present is generally employed in the instant compositions in approximate
weight
amounts of about 0.05 to 3% by weight, preferably about 0.05 to 2% by weight,
13
PCB','! ' ~' S
21~1~3'~
~PLi'1/ ~,; ~ " - '; ~,~.J
more typically employed in dentifrice compositions typically containing a
dental
abrasive and used in conjunction with brushing of the teeth, e.g. tooth pastes
(including creams), gels, powders and tablets. Amounts in excess of these
ranges
may be employed for thickening or gelling purposes. The preferred synthetic
anionic polymeric carboxylates (e.g. Gantrez) also enhance the antibacterial
effect
of the antiplaque agent. Other antibacterial-enhancing agents may also be
used.
Antibacterial-enhancing agents (AEAs), when present, enhance
delivery of the water-insoluble noncationic antibacterial agent to, and
retention
thereof on, oral surfaces, in accordance with a preferred embodiment of the
present invention. AEAs are employed in amounts effective to achieve such
enhancement preferably within the range in the oral composition of about
0.005%
to 4%, preferably about 0.1 % to 3%, more preferably about 0.5% to 2.5% by
weight.
The AEA may be a simple compound, preferably a polymerizable
monomer, more preferably a polymer, which latter term is entirely generic,
including for example oligomers, homopolymers, copolymers of two or more
monomers, ionomers, block copolymers, graft copolymers, cross-linked polymers
and copolymers, and the like. The AEA may be natural or synthetic, and water-
insoluble or preferably water (saliva) soluble or swellable (hydratable,
hydrogel
forming). It preferably has a (weight) average molecular weight of about 100
to
1,000,000, preferably about 1,000 to 1,000,000, more preferably about 2,000 or
2,500 to 250,000 or 500,000.
The AEA ordinarily contains at least one delivery-enhancing group,
which is preferably acidic such a sulfonic, phosphinic, or more preferably
phosphonic or carboyxlic, or salt thereof, e.g. alkali metal or ammonium, and
at
least one organic retention-enhancing group, preferably a plurality of both
the
delivery-enhancing and retention-enhancing groups, which latter groups
14
AME~QE~J ~1
WO 94/13254 21519 3 7 PCT/US93/11989
preferably have the formula - (X)n-R wherein X is O, N, S, SO, S02, P, PO or
Si
or the like, R is hydrophobic alkyl, alkenyl, acyl, aryl, alkaryl, aralkyl,
heterocyclic
or their inert-substituted derivatives, and n is zero or 1 or more. The
aforesaid
"inert-substituted derivatives" are intended to include substituents on R
which are
generally nonhydrophilic and do not significantly interfere with the desired
functions of the AEA as enhancing the delivery of the antibacterial agent to,
and
retention thereof on, oral surfaces such as halo, e.g. CI, Br, I, and carbo
and the
like. Illustrations of such retention-enhancing groups listed in Table 1.
WO 94113254 PCT/US93/11989
2~~~937
TABLE 1
n X -(X)nR
I - methyl, ethyl, propyl, butyl, isobutyl, t-butyl
0
cyclohexyl, allyl, benzyl, phenyl, chlorophenyl,
xylyl, pryridyl, furanyl, acetyl, benzoyl, butyryl,
tere hthalo I, etc.
1 O ethoxy, benzyloxy, thioacetoxy, phenoxy,
carboethox , carbobenz lox , etc.
N ethylamino, diethytamino, propylamido, benzylamino,
benzo lamido, hen lacetamido, etc.
S thiobutyl, thioisobutyl, thioallyl, thiobenzyl,
thiophenyl, thiopropionyl, phenylthioacetyl,
thiobenzo I, etc.
SO butylsulfoxy, allylsulfoxy, benzylsulfoxy,
hen Isulfox , etc.
sot butylsulfonyl, allylsulfonyl, benzylsulfonyl,
hen Isulfon I, etc.
P diethylphosphinyl, ethylvinylphosphinyl,
ethylallylphosphinyl, ethylbenzylphosphinyl,
eth Iphen Iphosphin I, etc.
PO diethylphosphinoxy, ethylvinylphosphinoxy,
methylallylphosphinoxy, methylbenzylphosphinoxy,
meth I hen I hos hinox , etc.
S trimethylsilyl, dimethylbutylsilyl,
i
dimeth Ibenz Isil I, dimeth Ivin Isil I, dimeth lall
Isil I, etc.
As employed herein, the delivery-enhancing group refers to one
which attaches or substantively, adhesively, cohesively or otherwise bonds the
AEA (carrying the antibacterial agent) to oral (e.g. tooth and gum) surfaces,
thereby "delivering" the antibacterial agent to such surfaces. The organic
retention-enhancing group, generally hydrophobic, attaches or otherwise bonds
the antibacterial agent to the AEA, thereby promoting retention of the
1 0 antibacterial agent to the AEA and indirectly on the oral surfaces. In
some
instances, attachment of the antibacterial agent occurs through physical
entrapment thereof by the AEA, especially when the AEA is a cross-linked
polymer, the structure of which inherently provides increased sites for such
entrapment. The presence of a higher molecular weight, more hydrophobic
16
CVO 94/13254
PCT/US93111989
cross-linking moiety in the cross-linked polymer still further promotes the
physical
entrapment of the antibacterial agent to or by the cross-linked AEA polymer.
Preferably, the AEA is a anionic polymer comprising a chain or
backbone containing repeating units each preferably containing at least one
carbon atom and preferably at least one directly or indirectly pendent,
monovalent delivery-enhancing group and at least one directly or indirectly
pendent monovalent retention-enhancing group geminally, vicinally or less
preferably otherwise bonded to atoms, preferably carbon, in the chain. Less
preferably, the polymer may contain delivery-enhancing groups and/or retention-
1 0 enhancing groups and/or other divalent atoms or groups as links in the
polymer
chain instead of or in addition to carbon atoms, or as cross-linking moieties.
It wilt be understood that any examples or illustrations of AEAs
disclosed herein which do not contain both delivery-enhancing groups and
retention enhancing groups may and preferably should be chemically modified
1 5 in known manner to obtain the preferred AEAs containing both such groups
and
preferably a plurality of each such groups. In the case of the preferred
polymeric
AEAs, it is desirable, for maximizing substantivity and delivery of the
antibacterial
agent to oral surfaces, that the repeating units in the polymer chain or
backbone
containing the acidic delivery-enhancing groups constitute at least about 10%,
2 0 preferably at least about 50%, more preferably at least about 80% up to
95% or
100% by weight of the polymer.
According to a preferred embodiment of this invention, the AEA
comprises a polymer containing repeating units in which one or more
phosphonic acid delivery-enhancing groups are bonded to one or more carbon
2 5 atoms in the polymer chain. An example of such an AEA is poly (vinyl
phosphonic acid) containing units of Formula I:
17
WO 94/13254 PCTIUS93/11989
- [CH 2 ~] -
~3 ~?
which however does not contain a retention-enhancing group. A group of the
latter type would however be present in poly(1-phosphonopropene) with units of
Formula II:
- ~~ ~ -
CH3 P03 HZ
A preferred phosphonic acid-containing AEA for use herein is poly (beta
styrene
phosphonic acid) containing units of Formula III:
Ph ~3
wherein Ph is phenyl, the phosphonic delivery-enhancing group and the phenyl
retention-enhancing group being bonded on vicinal carbon atoms in the chain,
or a copolymer of beta styrene phosphonic acid with vinyl phosphonyl chloride
2 0 having the units of Formula III alternating or in random association with
units of
Formula I above, or poly (alpha styrene phosphonic acid) containing units of
Formula IV:
18
CVO 94/13254 PCT/US93/11989
215.937
(IV)
- [CH 2 C_
Ph P43 ~I2
in which the delivery-enhancing and retention-enhancing groups are geminally
bonded to the chain.
These styrene phosphonic acid polymers and their copolymers with
other inert ethylenically unsaturated monomers generally have molecular
1 0 weights in the range of about 2,000 to 30,000, preferably about 2,500 to
10,000.
Such "inert" monomers do not significantly interfere with the intended
function of
any copolymer employed as an AEA herein.
Other phosphonic-containing polymers include, for example,
phosphonated ethylene having units of the Formula V:
(V)
- [ ~CH2)14CHPOgH2~n -
where n may for example be an integer or have a value giving the polymer a
molecular weight of about 3,000; and sodium poly(butene-4,4-diphosphonate)
having units of the Formula VI:
19
WO 94113254 PCTIUS93111989
~1~19'~'
(vl)
- ~~ 2 C_____~ -
Q-i2 CI I <( P03 Na)2
and poly (allyl bis (phosphonoethyl amine) having units of Formula VII:
(VII)
- ~~ 2 C___
N <( C2 H4 P03 H~) 2
1 0 Other phosphonated polymers, for example poly (allyl phosphono acetate),
phosphonated polymethacrylate, etc. and the geminal diphosphonate polymers
disclosed in EP Publication 0321233 may be employed herein as AEAs,
provided of course that they contain or are modified to contain the above-
defined
organic retention-enhancing groups. As previously indicated, the most
preferred
1 5 AEAs are synthetic anionic polymeric carboxylates.
The pH of the dentifrice preparations of this invention is generally in
the range of from about 4.5 to about 10 and typically from about 5.5 to 9. The
pH
is preferably in the range of from about 6 to about 8Ø It is noteworthy that
the
compositions of the invention may be applied orally at said pH ranges without
2 0 substantially decalcifying or otherwise damaging dental enamel. The pH can
be
controlled with acid (e.g. citric acid or benzoic acid) or base (e.g. sodium
hydroxide) or buffered (as with sodium citrate, benzoate, carbonate, or
bicarbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, etc).
WO 94/13254
PCT/US93/11989
In certain desirable forms of this invention, the dentifrice
composition may be substantially solid or pasty in character, such as tooth
powder, a dental tablet, a tooth paste (cream), or a dental gel. The vehicle
of
such solid or pasty dentifrice preparations typically contains an orally or
dentally
acceptable polishing material for use in conjunction with a brushing of the
teeth.
Examples of such polishing materials are water-insoluble sodium
metaphosphate, potassium metaphosphate, tricalcium phosphate, dihydrated
calcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate,
magnesium orthophosphate, trimagnesium phosphate, calcium carbonate,
1 0 aluminum silicate, zirconium silicate, silica, bentonite, and mixtures
thereof.
Other suitable polishing materials include the particulate thermosetting
resins
described in U.S. Patent No. 4,070,510 such as melamine-, phenolic-, and urea-
formaldehydes, and cross-linked polyepoxides and polyesters. Preferred
polishing materials include silica gel or colloidal silica, and complex
amorphous
1 5 alkali metal alumino-silicates.
When visually clear gels are desired, a polishing agent of colloidal
silica, such as those sold under the trademark SYLOID as Syloid 72 and Syloid
74 or under the trademark SANTOCEL as Santocel 100 and alkali metal
aluminosilicate complexes are particularly useful, since they have refractive
2 0 indices close to the refractive indices of gelling agent-liquid (including
water
and/or humectant) systems commonly used in dentifrices.
Many of the so-called "water-insoluble" polishing materials are
anionic in character and also include small amounts of soluble material. Thus,
insoluble sodium metaphosphate may be formed in any conventional manner.
2 5 The forms of insoluble sodium metaphosphate known as Madrell's salt and
Kurrol's salt are further examples of suitable materials. These metaphosphate
salts exhibit only a minute solubility in water, and therefore are commonly
referred to as insoluble metaphosphates (IMP). There is present therein a
minor
21
PCT/US93/11989
W O 94113254 z 1 ~ ~ 9 3 '~
amount of soluble phosphate material as impurities, usually a few percent such
as up to 4% by weight. The amount of soluble phosphate material, which is
believed to include a soluble sodium trimetaphosphate in the case of insoluble
metaphosphate, may be reduced or eliminated by washing with water if desired.
The insoluble alkali metal metaphosphate is typically employed in powder form
of a particle size such that no more than about 1 % of the material is larger
than
about 37 microns.
The polishing material is generally present in the solid or pasty
compositions in concentrations of about 10% to 99% by weight. Preferably, it
is
1 0 present in amounts ranging from about 10% to 75% by weight in toothpaste
or
gel and from about 70% to 99% by weight in tooth powder or tablet.
In a toothpaste, the topical liquid vehicle may comprise water and
humectant typically in an amount ranging from about 10% to 90% by weight of
the preparation. Glycerine, propylene glycol, sorbitol, polypropylene glycol
1 5 and/or polyethylene glycol (e.g. 400-600) exemplify suitable
humectants/carriers.
Also advantageous are liquid mixtures of water, glycerine and sorbitol. In
clear
gels where the refractive index is an important consideration, about 3 to 30%
by
weight of water, about 0 to 80% by weight of glycerine, and about 20 to 80% by
weight of sorbitol is preferably employed.
2 0 Toothpastes (creams) and gels typically contain in the topical
vehicle a natural or synthetic thickener or gelling agent in proportions of
about
0.1 to 10, preferably about 0.5 to 5% by weight. A suitable thickener is
synthetic
hectorite, a synthetic colloidal magnesium alkali metal silicate complex clay
available for example as Laponite (e.g. CP, SP 2002, D) marketed by Laporte
2 5 Industries Limited. Laponite D analysis shows, approximately by weight,
58.00%
Si02, 25.40% MgO, 3.05% Na20, 0.98% Li20, and some water and trace
metals. Its true specific gravity is 2.53 and it has an apparent bulk density
(g./ml.
at 8% moisture) of 1Ø
22
.w0 94/13254 21 ~ 19 3'~ , PCT/US93/11989
Other suitable thickeners include Irish moss, gum tragacanth,
starch, polyvinylpyrrolidone, hydroxyethylpropylcellulose, hydroxybutyl methyl
cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose (e.g.
available
as Natrosol), sodium carboxymethyl cellulose, and colloidal silica such as
finely
ground Syloid (e.g. 244).
It will be understood that, as is conventional, the oral preparations
are to be sold or otherwise distributed in suitably labeled packages. Thus, a
toothpaste, cream or gel will usually be in a collapsible tube, typically
aluminum,
lined lead or plastic, or other squeeze, pump or pressurized dispenser for
1 0 metering out the contents, having a label describing it, in substance, as
a
toothpaste, gel or dental cream.
In the aspect of the present invention wherein the oral composition
is a mouthwash or liquid dentifrice, substantially liquid in character, the
topical
vehicle, particularly in a mouthwash, is typically a water-alcohol mixture.
1 5 Generally, the weight ratio of water to alcohol is in the range of from
about 1:1 to
20:1, preferably about 3:1 to 10:1 and more preferably about 4:1 to 6:1. The
total
amount of the water-alcohol mixture in this type of preparation is typically
in the
range of from about 70 to 99.9% by weight. The alcohol is a non-toxic alcohol
such as ethanol or isopropanol, most preferably ethanol. The alcohol is
believed
2 0 to assist in dissolving water-insoluble noncationic antibacterial agents.
Flavoring
oil is also believed to perform the same function. Humectant such as glycerine
and sorbitol may be present in an amount of about 10 to 30% by weight. Liquid
dentifrices typically contain about 50 to 85% of water, may contain about 0.5
to
20% by weight of non-toxic alcohol and may also contain about 10 to 40% by
2 5 weight of humectant such as glycerine and/or sorbitol. Reference here to
sorbitol
refers to the material typically available commercially in 70% aqueous
solutions.
As indicated, the noncationic antibacterial agent is substantially
water-insoluble. However, in the present invention, particularly with the AEA,
23
WO 94/13254 PCT/US93/11989
21~1~3'~
such as polycarboxylate, present in the mouthwash or liquid dentifrice,
organic
surface-active agent, flavoring oil or non-toxic alcohol are believed to aid
dissolving the antibacterial agent to assist it to reach soft oral tissue at
or near the
gums as well as tooth surfaces. Organic surface-active agents and/or flavoring
oils may also assist dissolving the antibacterial agents as optional
ingredients in
oral dentifrice compositions.
Organic surface-active agents are used in the compositions of the
present invention to achieve increased prophylactic action, assist in
achieving
thorough and complete dispersion of the anticalculus agent throughout the oral
1 0 cavity, and render the instant compositions more cosmetically acceptable.
The
organic surface-active material is preferably anionic, nonionic or ampholytic
in
nature, and it is preferred to employ as the surface-active agent a detersive
material which imparts to the composition detersive and foaming properties.
Suitable examples of anionic surfactants are water-soluble salts of higher
fatty
1 5 acid monoglyceride monosulfates, such as the sodium salt of the
monosulfated
monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates
such
as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene
sulfonate, higher alkyl sulfoacetates, higher fatty acid esters of 1,2
dihydroxy
propane sulfonate, and the substantially saturated higher aliphatic acyl
amides
2 0 of lower aliphatic amino carboxylic acid compounds, such as those having
12 to
16 carbons in the fatty acid, alkyl or acyl radicals and alkoyl taurines, and
the
like. Examples of the last mentioned amides and taurates are N-lauroyl
sarcosine, and the sodium, potassium and ethanolamine salts of N-lauroyl, N-
myristoyl, or N-palmitoyl sarcosine which should be substantially free from
soap
2 5 or similar higher fatty acid material as well as N-methyl-N-cocoyl (or
oleoyl or
palmitoyl) taurines. The use of these sarcosinate compounds in the oral
compositions of the present invention is particularly advantageous since these
materials exhibit a prolonged and marked effect in the inhibition of acid
formation
24
WO 94/13254 ~ 21519 3 7 PCT/US93/11989
in the oral cavity due to carbohydrate breakdown in addition to exerting some
reduction in the solubility of tooth enamel in acid solutions.
Examples of water-soluble nonionic surfactants are condensation
products of ethylene oxide with various reactive hydrogen-containing
compounds reactive therewith having long hydrophobic chains (e.g. aliphatic
chains of about 12 to 20 carbon atoms), which condensation products
("ethoxamers") contain hydrophilic polyoxyethylene moieties, such as
condensation products of poly (ethylene oxide) with fatty acids, fatty
alcohols,
fatty amides, polyhydric alcohols (e.g. sorbitan monostearate) and
1 0 polypropyleneoxide (e.g. Pluronic materials).
Various other materials may be incorporated in the oral
preparations of this invention such as whitening agents, preservatives,
silicones,
chlorophyll compounds, other anticalculus agents, and/or ammoniated material
such as urea, diammonium phosphate, and mixtures thereof. These adjuvants,
1 5 where present, are incorporated in the preparations in amounts which do
not
substantially adversely affect the properties and characteristics desired
Significant amounts of zinc, magnesium and other metal salts and materials,
generally soluble, which would complex with the active components of the
instant invention are to be avoided.
2 0 Any suitable flavoring or sweetening material may also be
employed. Examples of suitable flavoring constituents are flavoring oils, e.g.
oil
of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus,
marjoram, cinnamon, lemon, and orange, and methyl salicylate. Suitable
sweetening agents include sucrose, lactose, maltose, dextrose, levulose,
2 5 sorbitol, xylitol, d-tryptophan, dihydrochalcones, sodium cyclamate,
perillartine,
APM (aspartyl phenyl alanine, methyl ester), saccharine and the like.
Suitably,
flavoring and sweetening agents may together comprise from about 0.1 % to 5%
by weight or more of the preparation.
WO 94113254 PCT/US93111989
In the preferred practice of this invention an oral composition
according to this invention such as a dentifrice is preferably applied as by
brushing regularly to dental enamel, such as every second or third day or
preferably from 1 to 3 times daily, at a pH of about 4.5 to 10, generally
about 5.5
to 9, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up
to
lifetime. The dentifrice is typically removed by rinsing with water after each
application.
The compositions of this invention can be incorporated in lozenges,
or in chewing gum or other products, e.g. by stirring into a warm gum base
1 0 topical vehicle or coating the outer surface of a gum base, illustrative
of which
may be mentioned jelutone, rubber latex, vinylite resins, etc., desirably with
conventional plasticizers or softeners, sugar or other sweeteners or
carbohydrates such as glucose, sorbitol and the like.
The topical vehicle or carrier in a tablet or lozenge is a non-
1 5 cariogenic solid water-soluble polyhydric alcohol (polyol) such as
mannitol,
xylitol, sorbitol, malitol, a hydrogenated starch hydrolysate, Lycasin,
hydrogenated glucose, hydrogenated disaccharides, and hydrogenated
polysaccharides, in an amount of about 90 to 98% by weight of the total
composition. Solid salts such as sodium bicarbonate, sodium chloride,
2 0 potassium bicarbonate or potassium chloride may totally or partially
replace the
polyol carrier.
Tableting lubricants, in minor amounts of about 0.1 to 5% by weight,
may be incorporated into the tablet or lozenge formulation to facilitate the
preparation of both the tablets and lozenges. Suitable lubricants include
2 5 vegetable oils such as coconut oil, magnesium stearate, aluminum stearate,
talc,
starch and carbowax.
Lozenge formulations contain about 2% gum as a barrier agent to
provide a shiny surface as opposed to a tablet which has a smooth finish.
26
251937 ~'CiI!~'~' 9: / ~ ~ ~ ~ 9
IF~;~-;;
~3 199
Suitable non-cariogenic gums include Kappa carrageenan, carboxymethyl
cellulose ,hydroxyethyl cellulose, Gantrez, and the like.
The lozenge or tablet may optionally be coated with a coating
material such as waxes, shellac, carboxymethyl cellulose, polyethylene/maleic
anhydride copolymer or Kappa-carrageenan to further increase the time it takes
the tablet or lozenge to dissolve in the mouth. The uncoated tablet or lozenge
is
slow dissolving, providing a sustained release rate of active ingredients of
about 3
to 5 minutes. Accordingly, the solid dose tablet and lozenge composition of
this
invention affords a relatively longer time period of contact of the teeth in
the oral
cavity with the active ingredients.
The following examples are further illustrative of the nature of the
present invention, but it is understood that the invention is not limited
thereto. All
amounts and proportions referred to herein and in the appended claims are by
weight.
EXAMPLE 1
The efficacy of N-methylpyrrolidone solutions to inhibit bacterial
plaque formation in vitro was assessed using the chemostat plaque model as
described in Gaffar et al., Am. J. Dent.. Vol. 3, Special Issue p. S7 (Sept.
1990).
The experimental apparatus includes a chemostat (Bioflo, Model C32), a source
of
supplementing growth media, a mixing chamber and several flow cells. The flow
cells were specifically designed to contain an experimental surface
(hydroxyapatite disks 12 mm x 1 mm thick) on which plaque formation was
measured.
A mixed continuous culture of five species of oral microorganisms
(A.viscosus LY7, S.S. mutans JBP, S. sang,~,tis 34, V_. p~pr~ ATCC 17745,
F. nucleatum 10953) was maintained in the chemostat according to conditions
27
AI~E~tD~ED T
WO 94/13254 PCT/US93/11989
described by Bradshaw et al., "Effects of Carbohydrate Pulses and pH on
Population Shifts with Oral Microbial Community In Vitro", J. Dent. Res.
9:1288-
1302 (1989). Modified BM medium diluted five-fold with distilled water and
supplemented with 2.5 g/I hog gastric mucin was used as the chemostat growth
medium. The bacterial effluent from the chemostat (1 ml/minute) was combined
with additional sterile modified BM media (1 ml/minute) containing 1 mM
sucrose
in a mixing chamber to achieve a total flow rate of 2 ml/minute. This mixture
was
then distributed to 2 flow cells, each with a flow rate of 1 ml/minute using a
peristaltic pump. Bacterial plaque formation was measured after 48 hours. The
1 0 flow cells were treated with a solution of 5% N-methylpyrrolidone for 30
seconds,
twice daily. A total of four treatments were given during the 48 hour
experimental
period; at 2.5, 20, 26.5 and 44 hours after the start of the flow through the
cell.
After 48 hours the cells were rinsed with distilled water for 15 minutes at a
flow
rate of 1 ml/minute. The hydroxyapatite disks were then removed for analysis.
1 5 The procedure was repeated except that the 5% N-methylpyrrolidone solution
was replaced by deionized distilled water as a control.
At the completion of each experiment, approximately 5 hours after
the last treatment, the flow cells were rinsed with distilled water for 15
minutes at
a flow rate of 1 ml/minute. Bacterial plaque formed on hydroxyapatite disks
was
2 0 removed by immersing the disks in 2 ml of 0.1 N NaOH in a shaking water
bath at
37°C for 45 minutes. After removing the disks, the samples were
sonicated to
disperse the plaque. Turbidity of the resulting solution was measured at 610
nm
in a spectrophotometer. A 0.1 ml sample was assayed for protein quantity using
the Pierce BCA assay kit (Pierce Rockford, IL.) A 1 ml aliquot of the sample
was
2 5 used for the determination of DNA according to the method of Labarca et
al., "A
Simple, Rapid Sensitive DNA Assay Procedure", Anal. Biochem., 102:344-352
( 1980).
28
WO 94/13254 PCT/US93/11989
Analysis of the plaque film on germanium prisms was done using
the method of attenuated total reflectance Fourier transform infrared
spectroscopy (ATR/FT-IR). At completion of the experiment, the germanium
prisms were air dried in a vertical position prior to analysis. A Perkin Elmer
(Norwalk, CT.), Model 1725 FT-Infrared Spectrometer was used for the ATR/FT-
IR measurements. The prisms were scanned from 4000 to 750 cm-1 at a scan
rate of 0.2 cm-1 and a resolution of 4 cm-1. The intensity bands (amide 1 and
2
bands) at 1650 and 1548 cm-1, reflecting mainly protein content, were used as
an estimate of the quantity of bacterial plaque present. The results are shown
in
1 0 Table 2.
29
WO 94/13254 PCT/US93111989
TABLE 2
Plaque Parameters %
Reduction vs. Placebos
Hydroxyapatite Germanium
Disks Surface2
Protein DNA
OD1 a /ml a /ml
Water Placebo - - -
5% N-methylpyrrolidone
59.6 28.8 29.7 29.6
1 OD = optical density
2 measured by ATR-FTIR (Attenuated Total Reflectance-Fourier
Transform Infrared Spectroscopy)
As shown in Table 2, twice a day treatment with a 5% solution of N-
1 0 methylpyrrolidone results in a substantial reduction in bacterial plaque
formed on
both hydroxyapatite and germanium surfaces as compared with the water
control.
1 5 EXAMPLES 2-5
Aqueous solutions of N-methylpyrrolidone having the
concentrations shown in Table 3 were tested on in vitro plaque formation using
the Saliva Flow Cell System.
2 0 The Saliva Flow Cell System was operated in the following manner
as described in part in Gaffar et al., Amer. J. Dent., Vol.3, Special Issue,
pp. S9-
S10 (Sept, 1990). A 100 ml glass jar of saliva was provided with a rubber
stopper, pre-perforated with two holes. A portion of a 1 ml Pyrex disposable
WO 94/13254 PCT/US93/11989
pipette, inserted into each hole, served as connectors. Plastic tubing having
an
internal diameter of 3.17 mm, served as the "vein" of the flow system.
The flow system was set up in an incubator (Precision Model 4) at
37°C, with the flow cells in a vertical position to minimize air
entrapment. Two
peristaltic pumps (Model P3), supplied with pre-cut silicone tubing (3.1 mm
internal diameter), were used to produce a steady and pulseless flow rate.
Pump
I was used to draw saliva from the dispenser through the flow cell and then
back
to the saliva reservoir for recirculation. Pump II was used to pulse the flow
cell.
Y-shaped connectors linked the two pumps. The flow from each pump was
1 0 alternately shut off during recirculation and pulsing.
Whole human saliva, supplemented with 10% TSB (tryptic soy
broth), was circulated through the flow system at a flow rate of 1 ml/minute,
corresponding to a shear stress of about 0.32 dynes-cm-2. Circulation was
performed for up to 72 hours, with TSB-saliva changes every 24 hours.
1 5 To assess the effect of N-methylpyrrolidone solutions on plaque
formation, at t=15 minutes, the flow cells were initially pulsed with test
samples at
a flow rate of 10 mllminute for 1 minute. Test solution residuals were removed
by
rinsing with the excess saliva, diluted another two-fold. TSB-saliva
circulation
was resumed after rinsing. Flow cells were treated twice within a 24 hour
period,
2 0 with subsequent change to fresh TSB-saliva every 24 hours. Treatments were
continued for 72 hours. The procedure was repeated except that the N-
methylpyrrolidone solution was replaced by deionized distilled water as a
control.
All treatments and saliva changes were performed without
2 5 disassembling the system or allowing the plates to go dry. Also, unless
otherwise stated, the flow rate was 1 ml/minute.
After 72 hours, the pump was stopped and the recirculating system
was disconnected from the dispenser. The flow cell was rinsed with deionized
31
WO 94!13254 ~ ~ ~ ~ ~ PCT/US93/11989
distilled water (single pass through) for 15 minutes to remove loosely bound
materials. Although the flow rates were the same for the deposition and rinse
phases, the shear stress was slightly lower in the rinse phase. The flow
system
was then disassembled and the test plates were air dried in a vertical
position
before analysis.
The results are shown in Table 3.
After drying for about 1 hour, the plates were analyzed using ATR-
infrared spectroscopy and ellipsometry, which gives the chemical composition
of
the plaque. The relative absorbance at 1540 cm-1 was used to quantify the
1 0 proteinaceous materials (bacteria) making up the plaque.
TABLE 3
REDUCTION VS. WATER
Plaque on Plaque film
N-methylpyrrolidone Germanium Surface! Thickness2
0 - -
1 % 22.3 Np3
5% 35.1 11.6
10% 57.8 45.3
20% 76.5 73.9
1 5 1 measured by ATR-FTIR spectroscopy
2 measured by ellipsometry
3 ND = not determined
32
WO 94/13254 PCT/US93I11989
As shown in Table 3, N-methylpyrrolidone significantly reduced the
amount of plaque on the substrate as compared with water, in a concentration
dependent manner.
EXAMPLE 6
A mouth rinse in accordance with the present invention was
prepared having the composition shown in Table 4.
TABLE 4
AMOUNT
COMPONENT
~~
Sodium Saccharin 0.03
GI cerine 10.00
Sodium Lau I Sulfate 0.25
N-meth I rrolidone 10.00
Triclosan 0.03
Flavorin oil 0.22
Water QS to 100
The composition was tested for plaque inhibiting effect using the
Saliva Flow Cell System described in connection with Examples 2-5. Two
control compositions were tested in the same manner. The first control
composition [Control (1 )] was the same as shown in Table 4 except for
omitting
N-methylpyrrolidone.
The second control composition [Control (2)] was the same as
shown in Table 4 except for omitting both N-methylpyrrolidone and Triclosan.
The results are shown in Table 5.
33
WO 94/13254 PCTIUS93l11989
TABLE 5
PERCENT REDUCTION
COMPOSITION PLAQUE ON PLAQUE FILM
GERMANIUM THICKNESS2
SURFACE1
Example 6 59 45
Control 1 48 35
Control 2 - -
1 measured by ATR-FTIR spectroscopy
2 measured by ellipsometry
As shown in Table 5, N-methylpyrrolidone in combination with
Triclosan has a greater plaque inhibiting effect than Triclosan alone, or a
1 0 composition containing neither N-methylpyrrolidone or Triclosan.
EXAMPLE 7
The effect of N-methylpyrrolidone on caries development was
1 5 tested in the following manner. A 30% by weight aqueous solution of N-
methylpyrrolidone (.1 ml) was used to test rat caries as described in Schmid
et
al., "Cariostatic Effects of Monofluorophosphate in Solutions and Dentifrices
in
Rats", J. Clin. Dent. Vol. No.3 pp. 75-82 (1989). The rat carries assay
employed
wearling rats exposed over a three week period to a cariogenic challenge
2 0 induced by a high sucrose diet and inoculation with acidogenic strains of
oral
bacteria. The rats were treated daily with the N-methylpyrrolidone solution or
34
WO 94/13254 ~ 1 ~ 19 3 7 PCT/US93I11989
deionized distilled water as a control and dental caries was evaluated at the
end
of the three week test period. The results are shown in Table 6.
TABLE 6
Mean Dentinal Smooth
Treatment Plaque Fissure Surface
Extent2 Lesions Lesions
Initial Advanced
Water 1.9 12.0 11.2 16.3
N-meth I rrolidone 0.31 7.41 3.3~ 3.0~
1 Significantly different from Water control (p<0.05).
2 Rated on a scale of 0 to 4 with 0 indicating no plaque formation and
4 the highest level of plaque formation.
1 0 The test data indicates that treatment with a 5°/a N-
methylpyrrolidone solution significantly reduced the amount of plaque formed
and the number of dental fissures and smooth surface caries as compared with
the water control.
WO 94/13254 PCT/US93/11989
~1~i'~~~'
EXAMPLE 8
The following mouth rinse composition was prepared in
accordance with the present invention:
INGREDIENTS AMOUNT (w/w)
Sodium Saccharin 0.03
Ethanol (95%) 10.00
Propylene Glycol 7.00
1 0 Triclosan 0.03
N-methylpyrrolidone 5.0
Sodium Lauryl Sulfate 0.25
Tauranol WSHP
(n-methyl-N-cocoyl taurine) 0.2
1 5 Gantrez S-96 1.92
NaOH (50% soln.) 0.12
Sorbitol 10.00
Flavoring Oil 0.145
Water QS to 100
The composition was prepared by combining the propylene glycol and ethanol.
Triclosan and the flavoring oil were added to the glycol/ethanol mixture to
form a
first mixture. All of the remaining components of the mouth rinse composition
were combined in water to form a second mixture. The first and second mixtures
2 5 were then combined to form the mouth rinse composition.
36
WO 94/13254 PCT/US93111989
EXAMPLE 9
The following dentifrice composition was prepared in accordance
with the present invention:
INGREDIENTS AMOUNT,~w/wl
Precipitated silica 23.00
Carboxymethylcellulose 1.60
N-methylpyrrolidone 10.00
1 0 Sorbitol (70%) 38.00
Gantrez S-96 2.50
Triclosan 2.50
Sodium lauryl sulfate 0.30
Sodium saccharine 0.20
1 5 Water QS to 100
EXAMPLE 10
2 0 The following dentifrice composition was prepared in accordance
with the present invention:
INGREDIENTS AMOUNT (w/w)
Precipitated silica 23.000
2 5 Carboxymethylcellulose 1.600
N-methylpyrrolidone 10.000
Sorbitol (70%) 38.000
Gantrez S-96 2.500
Na4P2O7 2.000
3 0 Sodium fluoride 0.243
Sodium lauryl sulfate 1.500
Sodium saccharine 0.200
Water QS to 100
37
WO 94/13254 PCT/US93/11989
EXAMPLE 11
The following mouth rinse composition was prepared in
accordance with the present invention.
INGREDIENTS AMOUNT (w/w)
Ethanol 10.00
N-methylpyrrolidone 5.00
PEG-40 Sorbitan diisostearate 0.20
Chlorhexidine digluconate 0.12
1 0 Sodium saccharine 0.03
G lycerine 10.00
Flavoring Oil 0.14
Deionized Water QS to 100
EXAMPLE 12
The following mouth rinse composition was prepared in
2 0 accordance with the present invention.
INGREDIENTS AMOUNT~w/w)
Ethanol 10.00
N-methylpyrrolidone 5.00
2 5 PEG-40 Sorbitan diisostearate 0.20
Cetylpyridinium chloride 0.12
Sodium saccharine 0.03
G lycerine 10.00
Flavoring Oil 0.14
3 0 Deionized Water QS to 100
This invention has been described with respect to preferred
embodiments and it will be understood that modifications and variations
thereof
3 5 obvious to those skilled in the art are to be included within the spirit
and purview
of this application and the scope of the appended claims.
38
